<?xml version="1.0" encoding="UTF-8"?>
<p>Despite earlier data of heterogenous safety and efficacy across different treatment groups, current therapies for chronic HCV infection are safe and effective across a variety of patient populations, with high SVR rates in decompensated cirrhosis (&gt;85%), end‐stage renal disease (&gt;95%), human immunodeficiency virus co‐infection (&gt;95%), or history of prior DAA failure (&gt;90%), status following liver transplantation (&gt;95%), and across all HCV genotypes (&gt;95%).
 <xref rid="hep41480-bib-0022" ref-type="ref">22</xref>, 
 <xref rid="hep41480-bib-0023" ref-type="ref">23</xref>, 
 <xref rid="hep41480-bib-0024" ref-type="ref">24</xref>, 
 <xref rid="hep41480-bib-0025" ref-type="ref">25</xref> High SVR despite multiple patient comorbidities targeting all viral genotypes thus raises the question about whether defining “special populations” or treatment subgroups is still a pertinent need.
</p>
